NCT05332483 (MA-EEC) is a Phase 1 clinical trial of Megestrol Acetate in Endometrial Cancer, sponsored by Sunnybrook Health Sciences Centre.

Who is sponsoring NCT05332483?

NCT05332483 is sponsored by Sunnybrook Health Sciences Centre.

What drugs are being tested in NCT05332483?

Interventions in NCT05332483: Megestrol Acetate.

What condition does NCT05332483 study?

NCT05332483 studies Endometrial Cancer.

Is NCT05332483 still recruiting?

NCT05332483 is currently terminated. Last updated 3 November 2023.

Last reviewed 2023-11-03 · How we verify

NCT05332483: MA-EEC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer

Terminated Phase 1 Last updated 3 November 2023

What this trial tests

Phase 1 trial testing Megestrol Acetate in Endometrial Cancer in 5 participants. Terminated before completion.

Timeline

5 July 2022

Primary endpoint
12 October 2023

12 October 2023

Quick facts

Lead sponsor	Sunnybrook Health Sciences Centre
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	5 July 2022
Primary completion	12 October 2023
Estimated completion	12 October 2023
Sites	1 location across Canada

Drugs / interventions tested

Megestrol Acetate (MEGESTROL ACETATE) — full drug profile →

Conditions studied

Endometrial Cancer — all drugs for Endometrial Cancer →

Sponsor

Sunnybrook Health Sciences Centre — full company profile →

Who can join

18 and older, female only, with Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single centre, single arm, open label, preoperative window of opportunity study. Grade 2 endometrioid endometrial carcinoma patients awaiting surgery will be prospectively recruited to receive a pre-operative progestin therapy course. Therapy response will be histologically evaluated and correlated with clinical and molecular data by comparison of responders vs. non-responders pre- and post-treatment tumor samples.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Oncological and reproductive outcomes of endometrial atypical hyperplasia and endometrial cancer patients undergoing conservative therapy with hysteroscopic resection: A systematic review and meta-analysis.
Zhao S, Zhang J, Yan Y, Tian L, et al · · 2024 · cited 8× · PMID 38382917 · DOI 10.1111/aogs.14815
Uterine-Conserving Treatment Options for Atypical Endometrial Hyperplasia and Early Endometrial Cancer.
Adjei NN, Bowen MB, Wilke RN, Yates MS, et al · · 2024 · PMID 39361076 · DOI 10.1007/s11912-024-01603-9

Verify or expand the search:

Other trials of Megestrol Acetate

Trials testing the same drug.

NCT07436793 — Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial · Phase 2 · not yet recruiting
NCT07254416 — A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients · Phase 4 · not yet recruiting
NCT06998758 — Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC · Phase 3 · recruiting
NCT05538897 — Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recur · Phase 1, PHASE2 · active not recruiting
NCT05380479 — Mirtazapine Versus Megestrol Acetate in Treatment of Anorexia-cachexia in Advanced Cancer Patients. · Phase 2 · unknown

Other recruiting trials for Endometrial Cancer

Currently open trials in the same condition.

NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P · recruiting
NCT07377734 — Intrauterine Injection of Type III Collage in FST of EC/AEH · Phase 2 · recruiting
NCT07319429 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification · Phase 2, PHASE3 · recruiting
NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer · recruiting

Other Sunnybrook Health Sciences Centre trials

Trials by the same sponsor.

NCT07478705 — Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid · NA · not yet recruiting
NCT07376018 — Ketogenic Diet and Neuromodulation in Treatment Resistant Depression · NA · not yet recruiting
NCT07350278 — Comparing Virtual Reality Simulation to High Fidelity Simulation as an Educational Modality for Electroconvulsive Therap · NA · not yet recruiting
NCT07191145 — Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) · Phase 3 · not yet recruiting
NCT07308587 — Evaluation of Intercostal Neuralgia in Patients With Chest Tube Insertion After Traumatic Rib Fracture · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05332483 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sunnybrook Health Sciences Centre
Last refreshed: 3 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05332483.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing